Article Text

Download PDFPDF
Current role of positron emission tomography in thoracic oncology
  1. Val J Lowea,
  2. Keith S Naunheimb
  1. aDepartment of Nuclear Medicine, bDepartment of Surgery, cSt Louis University Health Sciences Center, St Louis, Missouri 63110–0250, USA
  1. Dr V J Lowe.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Positron emission tomography (PET) has been in existence and continuously developing over the past 20 years. In the last few years steady advances in the technology used for PET and complementary progress in supporting computer equipment have led to the ability to perform whole body imaging with this modality. With this evolution has come an improved capability for the diagnosis, staging, and post-treatment surveillance of malignancies in the thoracic cavity. This report will review the current status of PET imaging for the investigation of thoracic oncology.

PET scan technique

PET imaging involves the use of specialised radiation sensitive cameras which detect specific radioactive isotopes that decay by positron emission. Most of the common molecules involved in organic processes can be labelled with positron emitting isotopes. Atoms of low atomic number such as carbon, oxygen, nitrogen, and fluorine have positron emitting isotopes. Molecules of specific functional import, labelled with positron emitting isotopes, can be injected intravenously into patients and an image of their distribution can be obtained using a PET camera. Although many different tracers can be manufactured and have been utilised to evaluate malignancy, this review will focus on the use of one tracer, 18F-fluorodeoxyglucose (FDG), which is the most widely used for detection of malignancy.

Malignant tumours usually demonstrate rapid cell proliferation with a proportionally increased cellular metabolism. Physiologically, this translates into increased glucose metabolism in malignant cells, a finding first reported in the 1930s.1-3 Comparable enhancements of glucose and FDG uptake in malignant cells have permitted the identification of malignancy using PET imaging.4 A unique feature of FDG as a marker of glucose metabolism is the fact that, after FDG phosphorylation, FDG-6-PO4 does not proceed further in the metabolic pathway but remains trapped within tumour cells, thus becoming a marker of metabolism. This persistence of the tracer …

View Full Text